Literature DB >> 28294412

Association of 758 G/A polymorphism of 3'untranslated region of prohibitin with risk of gastric cancer.

Fenfen Xiang1, Zhenhua Ni2, Yueping Zhan2, Jian Xu2, Rong Wu1, Xiangdong Kang1.   

Abstract

BACKGROUND: A polymorphic variant allele (T-allele) in the 3'-UTR of prohibitin (C-to-T at nucleotide 729) was reported to be associated with an increased risk of breast cancer. However, the association between the 3'-UTR polymorphism of prohibitin and the susceptibility to gastric cancer remains unknown. Thus, we investigated the distribution of prohibitin genotypes in Chinese patients with gastric cancer and subsequently analyzed the association between the 3'-UTR polymorphism of prohibitin and the risk of gastric cancer in that population.
METHODS: The distribution of 3'-UTR polymorphism of prohibitin in 82 gastric cancer patients was determined by sequencing and compared with that of 171 healthy controls. Luciferase reporter assay was used to investigate the effect of 3'-UTRs variant on PHB expression.
RESULTS: Our study discovered two major polymorphic sites in the 3'-UTR of prohibitin (C-to-T at nucleotide 729 and G to A at nucleotide 758). The C/T polymorphism at 729 site was not associated with the increased risk of gastric cancer (P=.961, OR=1.044, 95%CI: 0.187-5.818); however, G/A polymorphism at nucleotide 758 increased the risk of gastric cancer (P=.017, OR=1.923, 95%CI: 1.119-3.305). Luciferase reporter constructs containing the 758A allele showed higher luciferase activity compared with the wild-type allele, which indicated that 758 G>A in 3'-UTR increased PHB expression.
CONCLUSIONS: The G to A transition but not the C-to-T transition in the 3'-UTR of prohibitin was associated with an increased risk of gastric cancer in Chinese population.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  3′-UTR; cancer risk; gastric cancer; polymorphism; prohibitin

Mesh:

Substances:

Year:  2017        PMID: 28294412      PMCID: PMC6816903          DOI: 10.1002/jcla.22182

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  13 in total

1.  Prohibitins act as a membrane-bound chaperone for the stabilization of mitochondrial proteins.

Authors:  L G Nijtmans; L de Jong; M Artal Sanz; P J Coates; J A Berden; J W Back; A O Muijsers; H van der Spek; L A Grivell
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

2.  Prohibitin 3' untranslated region polymorphism and breast cancer risk.

Authors:  Ian G Campbell; James Allen; Diana M Eccles
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-11       Impact factor: 4.254

3.  Identification of prohibitin as a potential biomarker for colorectal carcinoma based on proteomics technology.

Authors:  Debo Chen; Fenglin Chen; Xingrong Lu; Xiaosong Yang; Zhongbin Xu; Jie Pan; Ying Huang; Huiming Lin; Pan Chi
Journal:  Int J Oncol       Date:  2010-08       Impact factor: 5.650

4.  MicroRNA 345, a methylation-sensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer.

Authors:  Jie-Ting Tang; Ji-Lin Wang; Wan Du; Jie Hong; Shu-Liang Zhao; Ying-Chao Wang; Hua Xiong; Hui-Min Chen; Jing-Yuan Fang
Journal:  Carcinogenesis       Date:  2011-06-10       Impact factor: 4.944

5.  Prohibitin in breast cancer cell lines: loss of antiproliferative activity is linked to 3' untranslated region mutations.

Authors:  E R Jupe; X T Liu; J L Kiehlbauch; J K McClung; R T Dell'Orco
Journal:  Cell Growth Differ       Date:  1996-07

6.  Prohibitin: a potential biomarker for tissue-based detection of gastric cancer.

Authors:  Xiangdong Kang; Long Zhang; Jian Sun; Zhenhua Ni; Yanchun Ma; Xiaobo Chen; Xia Sheng; Teng Chen
Journal:  J Gastroenterol       Date:  2008-08-17       Impact factor: 7.527

Review 7.  Epidemiology of stomach cancer.

Authors:  Hermann Brenner; Dietrich Rothenbacher; Volker Arndt
Journal:  Methods Mol Biol       Date:  2009

8.  Prohibitin 3' untranslated region polymorphism and breast cancer risk in Australian women.

Authors:  Amanda B Spurdle; John L Hopper; Xiaoqing Chen; Margaret R E McCredie; Graham G Giles; Beth Newman; Georgia Chenevix-Trench
Journal:  Lancet       Date:  2002-09-21       Impact factor: 79.321

9.  Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism.

Authors:  Anna Jakubowska; Jacek Gronwald; Janusz Menkiszak; Bohdan Górski; Tomasz Huzarski; Tomasz Byrski; Axel Benner; Jan Lubiński; Rodney J Scott; Ute Hamann
Journal:  BMC Cancer       Date:  2008-04-08       Impact factor: 4.430

10.  miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.

Authors:  Jakob V Schou; Simona Rossi; Benny V Jensen; Dorte L Nielsen; Per Pfeiffer; Estrid Høgdall; Mette Yilmaz; Sabine Tejpar; Mauro Delorenzi; Mogens Kruhøffer; Julia S Johansen
Journal:  PLoS One       Date:  2014-06-18       Impact factor: 3.240

View more
  3 in total

1.  Reduced expression of circRNA hsa_circ_0003159 in gastric cancer and its clinical significance.

Authors:  Mengqian Tian; Ruoyu Chen; Tianwen Li; Bingxiu Xiao
Journal:  J Clin Lab Anal       Date:  2017-06-15       Impact factor: 2.352

2.  Clinical values of circular RNA 0000181 in the screening of gastric cancer.

Authors:  Qianfu Zhao; Shijun Chen; Tianwen Li; Bingxiu Xiao; Xinjun Zhang
Journal:  J Clin Lab Anal       Date:  2017-09-22       Impact factor: 2.352

3.  Association of peripheral blood leukocyte KIBRA methylation with gastric cancer risk: a case-control study.

Authors:  Yan Zhang; Haibo Zhou; Hongxu Sun; Jie Chen; Di Huang; Xu Han; Xiyun Ren; Shangqun Lin; Qing Fan; Wenjing Tian; Yashuang Zhao
Journal:  Cancer Med       Date:  2018-04-16       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.